Position in LLY
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$107,915,118
+$25,491,773 QoQ
Shares Held
89,972
+0.4% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
1.52%
of 13F equity value
Holder Rank
#371
of 4,605 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026J. Safra Sarasin Holding AG holds $642,035,981 across 11 Drug Manufacturers - General names. LLY ranks #3 (16.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
987,390 | $126,879,614 | |
| 2 | JNJ |
Johnson & Johnson
|
456,968 | $116,056,159 | |
| 3 | LLY |
ELI LILLY & Co
This page
|
89,972 | $107,915,118 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
690,777 | $87,272,764 | |
| 5 | ABBV |
AbbVie Inc.
|
342,816 | $86,266,214 | |
| 6 | AMGN |
Amgen Inc
|
206,411 | $74,745,548 | |
| 7 | AZN |
Astrazeneca PLC
|
169,998 | $32,235,020 | |
| 8 | NVO |
Novo Nordisk A S
|
134,442 | $6,445,149 |
All Filings in LLY
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $107,915,118 | 89,972 | Shares | Defined | 2026-07-31 | |
| 2026-03-31 | $82,423,345 | 89,613 | Shares | Defined | 2026-05-04 | |
| 2025-12-31 | $88,476,259 | 82,328 | Shares | Defined | 2026-01-15 | |
| 2025-09-30 | $53,607,617 | 70,259 | Shares | Defined | 2025-11-03 | |
| 2025-06-30 | $63,668,109 | 81,675 | Shares | Defined | 2025-07-21 | |
| 2025-03-31 | $62,450,355 | 75,614 | Shares | Defined | 2025-05-09 | |
| 2024-12-31 | $62,510,384 | 80,972 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $82,807,922 | 93,469 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $64,208,639 | 70,919 | Shares | Defined | 2024-07-30 | |
| No filing history on record for this holder in this stock. | ||||||